Business As Usual...Until It Isn’t: MDPNP’s Impact on 340B with Julie Crozier, CEO of Secure340B

Send us a text

Schedule an Rx Assessment

With Medicare’s Maximum Fair Price (MFP) rebates officially underway and the 340B rebate mechanism on hold, pharmacy owners are left navigating one of the grayest areas the industry has seen in years.

In this episode, Scotty Sykes, CPA, CFP®, Bonnie Bond, CPA, MBA, and Austin Murray sit down with Julie Crozier, CEO at  @secure340b to unpack how MDPNP is colliding with 340B and what pharmacies should be paying attention to right now.

We cover:

• How MDPNP and MFP rebates are flowing today
• The duplicate discount problem no one is reconciling
• Beacon’s role and why future reconciliation risk matters
• Dispensing fee pressure, CE relationships, and contract implications
• Practical considerations if TPAs or covered entities push for carve-outs

And more!

More About Our Guest:

As CEO of Secure340B, Julie is responsible for formulating and executing strategic plans and technology to deliver critical and timely intel to 340B stakeholders.

Julie has over 25 years of pharmacy experience including co-founding, growing and leading a pharmacy software company, Macro Helix, which was acquired by McKesson Corp (NYSE: MCK) in 2012.

Julie also has experience in retail pharmacy, long-term care, state Medicaid programs and healthcare revenue cycle. She holds a Bachelor’s in Pharmacy and a Master’s in Pharmacy Administration from The University of Texas at Austin.

Julie serves on the board at Crossroads Community Services, a food pantry, and lives in Dallas, Texas with her husband and 2 daughters.

Stay connected with Julie and Secure340B:

Julie Crozier LinkedIn

Secure340B Website

Secure340B Facebook

Secure340B LinkedIn

Secure340B Instagram

Stay connected with us:

Facebook

YouTube 

LinkedIn

Instagram

More resources on this topic:

Podcast - Driving Independent Pharmacy Profitability in 2026

Podcast – The Startup Compounding Pharmacy Playbook

Podcast – Inside the Fight for Compounding: Advocacy, Growth, and Regulation